The 2013 reverse merger was a huge flaw that has created the opportunity we have today. We "only" need $ 8 to $12 million to get all 200 applications of AC5 approved in US and Europe.
With Dr. Norchi's background of being a MIT MBA and former portfolio manager at $ 4 Billion Putnam healthcare fund it would have been so easy to raise $20 million in straight up IPO and been done with it. Instead they did complicated warrant structure. This benefited us with the opportunity.
Arch has totally changed in last 9 months with a fleet of potential products beyond AC5's 200 applications that no one is focusing on yet.
News 
Market Data 
Discover 
